Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Banco Santander SA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.9 (market cap $8.04B), while Banco Santander SA trades at $13.71 (market cap $195.40B). The key difference: Banco Santander SA is far larger — about 24.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Banco Santander SA pays a 2.04% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SAN | |
|---|---|---|
Market Cap | $8.04B | $195.40B |
Sector | Health | Financials |
52-Week High | $339.75 | $14.37 |
52-Week Low | $241.71 | $8.31 |
Enterprise Value | $7.85B | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Banco Santander (SAN) trades at $13.66, down 1.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.4144, beating expectations, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value. The stock shows a P/E of 13.57 and P/B of 1.62, indicating reasonable valuation relative to peers.
The outlook for SAN is positive, supported by record profitability, strategic acquisitions, and cost-saving measures. However, risks include declining cash flows, regulatory scrutiny in Spain, and macroeconomic pressures on loan growth. Analyst consensus is bullish with 64% buy ratings, but investors should monitor execution on efficiency targets and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
